World Health Organization Raises Concern Over Severe Lack of Weight-Loss Jabs

Less than 10% of people who could benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it publishes its initial recommendations on the medications.

Given over a billion people worldwide now classified as obese, it is advocating for broader and more equitable access to this class of drugs.

According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.

"The latest guidelines acknowledges that excess weight is a lifelong illness that can be addressed with thorough and lifelong care," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are major obstacles to universal access to the jabs that can aid individuals in losing considerable weight, says the body.

Skinny Jab Shortage

Even in the current most favorable outlook, the production of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, as stated by the WHO.

The recommendation encourages governments and firms to widen availability, via strategies like licensing agreements.

The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is set to lapse in several countries in 2026.

How Weight-Loss Drugs Work

GLP-1 drugs imitate a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so individuals reduce food intake.

Patients usually begin shedding pounds within a few weeks of beginning the weekly injections.

Evidence suggests users may put most of the weight back on after a year of halting the treatment, because their normal food cravings come back.

To be carrying excess weight increases your likelihood for experiencing diseases, such as diabetes, heart disease, stroke, and specific malignancies.

Excess weight concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the WHO.